Metoprolol (Lopressor, Toprol-XL) and CYP2D6 Pharmacogenomics

What Is Metoprolol?

Metoprolol (brand names Lopressor and Toprol-XL) is a selective beta-1 adrenergic blocker and the most prescribed beta-blocker in the United States. It is used to treat hypertension, heart failure, angina pectoris, post-myocardial infarction management, and certain arrhythmias. By blocking beta-1 receptors in the heart, metoprolol reduces heart rate, blood pressure, and myocardial oxygen demand.

What makes metoprolol relevant to pharmacogenomics is that it is extensively metabolized by CYP2D6, a highly polymorphic cytochrome P450 enzyme. CYP2D6 accounts for approximately 70-80% of metoprolol clearance, making the drug one of the most CYP2D6-dependent medications in clinical use. Patients with altered CYP2D6 activity can experience dramatically different drug exposure levels at the same dose.

Why Metoprolol Response Varies by Genetics

CYP2D6 is the primary metabolic pathway for metoprolol, responsible for approximately 70-80% of its biotransformation. Because of this heavy reliance on a single enzyme, CYP2D6 genetic variation has a pronounced effect on metoprolol plasma concentrations. Poor metabolizers — individuals with little or no CYP2D6 enzyme activity — can have 3-5 times higher plasma levels of metoprolol compared to normal metabolizers at the same dose. This elevated exposure leads to exaggerated beta-blockade, which can manifest as bradycardia, hypotension, and significant fatigue.

On the other end of the spectrum, ultrarapid metabolizers clear metoprolol so quickly that standard doses may produce subtherapeutic drug levels, potentially resulting in inadequate heart rate and blood pressure control. Understanding this metabolic variability is central to how pharmacogenomic testing can guide beta-blocker prescribing.

CYP2D6 and Beta-Blocker Metabolism

CYP2D6 metabolizer status determines how efficiently metoprolol is cleared from the body. The clinical impact spans a wide range depending on phenotype:

• Normal Metabolizer: Standard metoprolol clearance. Typical beta-blocker response at recommended doses. No genotype-based adjustments needed.
• Intermediate Metabolizer: Moderately reduced CYP2D6 activity leading to decreased metoprolol clearance. May experience stronger beta-blockade at standard doses, including more pronounced heart rate reduction and blood pressure lowering.
• Poor Metabolizer: 3-5 times higher metoprolol exposure compared to normal metabolizers. Significantly increased risk of bradycardia, hypotension, and fatigue. The DPWG recommends dose reduction to a maximum of 25% of the standard dose, or switching to an alternative beta-blocker not dependent on CYP2D6 (e.g., bisoprolol).
• Ultrarapid Metabolizer: Rapid CYP2D6 clearance may result in subtherapeutic metoprolol levels at standard doses. Patients may experience insufficient beta-blockade with inadequate heart rate and blood pressure control.

It is important to note that not everyone with altered CYP2D6 function will experience clinical consequences. Genetics is one factor among several, including dose, body weight, renal function, concurrent medications, and comorbidities. The goal of genotype-guided prescribing is to reduce risk, not to predict outcomes with certainty. For a plain-language explanation of how reduced-function genotypes affect drug processing, see what does poor metabolizer mean.

Clinical Guideline Summary

CPIC has not yet published a formal guideline specific to metoprolol. However, the Dutch Pharmacogenetics Working Group (DPWG) has published actionable CYP2D6-based recommendations for metoprolol prescribing. The DPWG recommendations are:

• Normal Metabolizer: Standard metoprolol prescribing. No genotype-based adjustments needed.
• Intermediate Metabolizer: Use with caution. Monitor for exaggerated beta-blockade effects such as bradycardia and hypotension. Consider dose reduction if adverse effects occur.
• Poor Metabolizer: Reduce metoprolol dose to a maximum of 25% of the standard dose, or select an alternative beta-blocker not metabolized by CYP2D6, such as bisoprolol or atenolol. If metoprolol is continued, titrate slowly with close monitoring of heart rate and blood pressure.
• Ultrarapid Metabolizer: Increased metoprolol doses may be required for adequate effect. Alternatively, consider a beta-blocker not dependent on CYP2D6 metabolism. Monitor clinical response closely.

These DPWG recommendations reflect the strong evidence linking CYP2D6 genotype to metoprolol pharmacokinetics and clinical outcomes. While CPIC has not issued a metoprolol-specific guideline, the DPWG classification is widely referenced in pharmacogenomic practice.

Clinical Context and Evidence

Metoprolol is one of the most extensively studied CYP2D6 substrates in pharmacogenomics. Kirchheiner et al. (2004; PMID: 14615351) demonstrated that CYP2D6 poor metabolizers had 3-5 times higher area under the curve (AUC) values for metoprolol compared to extensive (normal) metabolizers, confirming the strong dependence of metoprolol clearance on CYP2D6 activity.

Bijl et al. (2009; PMID: 19153681) conducted a population-based study that found a significant association between CYP2D6 genotype and metoprolol-related adverse events, including bradycardia and fatigue, in patients prescribed metoprolol in routine clinical care. This study provided real-world evidence supporting the clinical relevance of CYP2D6 genotyping for metoprolol.

The breadth and consistency of evidence across multiple studies and populations make the CYP2D6-metoprolol interaction one of the best-characterized drug-gene relationships in clinical pharmacogenomics.

Understanding Your Results

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can determine your CYP2D6 diplotype and metabolizer phenotype and report whether metoprolol is flagged as a drug-gene interaction. Your Medication Safety Report will include your CYP2D6 diplotype, predicted phenotype, and whether metoprolol is identified as a gene-drug interaction relevant to your genotype. You can view a sample report to see the format.

Beta-blocker prescribing involves balancing cardiovascular benefit against tolerability. If your report identifies altered CYP2D6 metabolism, this does not mean you should stop taking metoprolol — dose adjustments or alternative beta-blockers may be appropriate. Always discuss results with your healthcare provider. See our methodology and limitations pages for important context about consumer-grade analysis. To see how DecodeMyBio compares to other pharmacogenomic testing options, visit our testing comparison page.

Related Resources

• CYP2D6 gene — variants, phenotypes, and drug metabolism
• Codeine and CYP2D6 — another CYP2D6-dependent medication
• Tramadol and CYP2D6 pharmacogenomics
• Venlafaxine and CYP2D6 pharmacogenomics
• What to do with your 23andMe raw data

Frequently Asked Questions